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Abstract
Background: The results of palliative chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) in patients with advanced breast cancer who received adjuvant therapy with the same regimen were 
investigated.
Results: Of 47 patients, 14 (30%) achieved an objective remission (median duration 9.5, range 5-21  months) and 8 
(17%) stabilisation of disease (median duration 6, range 3-17  months). Objective remissions were observed in 
premenopausal as well as in postmenopausal women, in patients with all categories of dominant localisation of 
disease and regardless of the oestradiol receptor status of the primary tumour or eventual previous endocrine 
therapy. One of 4 and 13 of 43 patients who started palliative chemotherapy within or later than 12 months after the 
last adjuvant course obtained an objective remission. The median survival time from start of therapy of all treated 
patients was 12 (range 1-40) months. Patients with an objective remission or stable disease and patients with 
progressive disease had a median survival time of 20 (range 6-40) and 6 (range 1-35) months respectively 
( p <  0.0001).
Conclusions: Palliative treatment with CMF should not be rejected for patients who have relapsed after adjuvant 
chemotherapy with the same modality.
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1. Introduction
Chemotherapy with cyclophosphamide, metho­
trexate and 5-fluorouracil (CMF) is used as
* Corresponding author.
standard adjuvant treatment in premenopausal 
women with axillary-node-positive primary breast 
cancer. Patients who subsequently develop metas­
tasis might be candidates for palliative chemo­
therapy. It is questionable whether reinstitution 
of CMF in this group of patients is a good choice.
In the literature several authors have studied 
the efficacy of systemic chemotherapy after the
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use of adjuvant chemotherapy in patients with 
advanced breast cancer [1-5], The studies are 
often hampered by small numbers of patients and 
by the fact that palliative and adjuvant therapy 
were not the same.
In this article the results of palliative 
chemotherapy with CMF in 47 patients with ad­
vanced breast cancer, previously treated with the 
same regimen as an adjuvant to surgery, are 
reported.
2. Patients and methods
Fifty-six patients previously treated with adju­
vant CMF received palliative CMF for advanced 
disease. The results of this therapy have been 
analyzed retrospectively.
The patients were treated in the University 
Hospital of Nijmegen and in the St. Anna Hospi­
tal, Oss, between 1976 and 1992.
Adjuvant CMF was given as “ low dose5’ and 
“classical” before and after 1984 respectively and 
consisted of cyclophosphamide, days 1-14 orally, 
75 and 100 m g /m 2 and on days 1 and 8 intra­
venous methotrexate, 30 and 40 m g/m 2 and 5- 
fluorouracil 500 and 600 m g/m 2 i.v. respectively. 
Cycles were repeated every 28 days. The number 
of cycles was 12 or more for the low dose and 6 
for the classical CMF modality. Thus the in­
tended total dose of CMF in the low-dose group 
during the first 6 cycles was about 11% of that of 
the classical one. But after 1 year this figure was
144%.
Palliative CMF as first-line chemotherapy was 
given as the classical modality. Indications were 
progressive metastatic or local/regional recur­
rent disease, steroid hormone receptor negativity 
or not (longer) sensitive to endocrine therapy. 
Patients with massive liver involvement or central 
nervous (CNS) metastasis received anthracyclins 
and CNS irradiation respectively. Patients should 
have received at least two cycles to be evaluable 
for response, unless there was clear progression 
after one cycle.
Response to therapy was established according 
to criteria of the WHO [6]. Age and menopausal 
status were considered at the start of palliative
CMF treatment. Postmenopausal was defined as 
> 1 year after the last menstruation or according 
to postmenopausal gonadotrophin levels in serum. 
Oestradiol receptor activity (ER) was determined 
in tissue of the primary tumour or metastasis with 
the dextran-coated charcoal ligand binding assay 
and Scatchard plot analysis with a cut-off value of
10 fmol/mg protein [7].
The estimated duration of response and sur­
vival was calculated according to Kaplan and 
Meier [13]. Tests for statistical significance were 
performed using SAS (Statistical Analyzing Sys­
tem) statistical software [8],
3. Results
University Hospital, Nijmegen
Between 1976 and 1992, adjuvant therapy with 
CMF was given to 226 women. Until 1994, 
local/regional or distant relapses have been ob­
served in 111 patients. Of those women, 48 were 
treated with palliative CMF. The main reasons 
for withholding this therapy in the remaining 
patients were: no indication; refusal or relapse 
during adjuvant CMF therapy. Of the 48 treated 
patients, 8 were not evaluable for response to 
therapy because of: lack of tumour parameters 
(n = 2); less than 2 cycles of therapy (n = 3, for 
subjective toxicity); early death (n = 2, fatal pul­
monary embolism and unknown cause); and in­
sufficient therapy (n = 1). Thus, from this hospi­
tal 40 patients could be included in the analysis. 1
St. Anna Hospital, Oss
The protocols for treatment of patients with 
breast cancer were identical to those in the Uni­
versity Hospital. From this hospital 8 patients 
eligible for analysis could be traced. One patient 
died within 2 months due to pneumonia. Seven 
were evaluable for response.
1 One of these patients died after 1 month of therapy 
because of rapidly progressive disease. This was regarded as 
(early) failure to treatment.
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Table 1
Pre-treatment characteristics and response to therapy
Objective remission + 
stable disease/ 
treated patients
%
Menopausal status
Premenopausal 5 /9 56
Postmenopausal 16/33 48
Unknown 1/5 20 NS
ER status
Positive 11/21 50
Negative 10/21 48
Unknown 1/5 20 NS
Dominant site of disease
Soft tissue 2 /5 40
Bone 9/13 69
Viscera 11/29 38 NS
Prior endocrine therapy
Yes 15/28 54
No 7/19 37 NS
Disease-free interval (DFI)
< 12 months 1 /4 25
>12 months 21/43 49
Adjuvant CMF dose
Low dose 13/23 56
Classical dose 9/24 38 NS
Results o f  palliative CMF (n — 47)
The interval between the two CMF regimens 
varied between 1 and 83 months. Prior palliative 
endocrine therapy was given to 28 patients 
(tamoxifen, n = 25 an d /o r oophorectomy).
Two of the 47 patients achieved a complete 
remission and 12 patients had a partial remission 
during treatment with CMF. The objective remis­
sion rate (CR plus PR) was 30% (14/47), with a 
median duration of response of 9.5 (range 5-21) 
months. In 8 patients the previously progressive 
disease stabilized with a median duration of 6 
(range 3-17) months. The median survival time 
of patients who achieved an objective remission 
and stable disease was 20 (range 6-40) months, 
while the 25 patients who continued to have 
progressive disease had a median survival of only 
6 (range 1-35) months (p  < 0.0001).
The median survival time for the entire group 
was 12 (range 1-40) months.
A complete remission was found in 2 patients 
with visceral disease. The objective remission 
rates for patients with soft tissue, bone or visceral
Table 2
Response to palliative chemotherapy in relation to previous adjuvant chemotherapy
Ref.
No.
No. of 
patients
Adjuvant
therapy
Palliative
therapy
Objective
remission
n %
(A) Palliative therapy same as adjuvant therapy 
1 29
This study 47
3 20
4 44 
Total 140
CMF 
CMF 
A /FA  C 
CFP
(B) Palliative therapy different from adjuvant therapy
3
4 
6 
7
Total
18
156
15
25
214
A
CFP
various
CMF
CMF 
CMF 
A /F A  C 
CFP
various
various
various
Mi
12
13
8
11
45
7
43
4
7
61
41
27
40
25
32
39
28
27
28 
28
(C) No adjuvant therapy
1 93
10 53
11 73
12 114 
Total 333
CMF
CMF
CMF
CMF
49
28
33
55
165
53
53
45
48
50
C = cyclophosphamide; A = adriamycin; M -  methotrexate; P = prednisone; F  = 5-fluorouracil; Mi — mitoxantrone.
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disease were 20, 41 and 28%, respectively (p >  
0.1).
Four patients started palliative CMF chemo­
therapy within 12 months after finishing adjuvant 
CMF treatment. One of those patients achieved a 
partial remission; the other 3 patients continued 
with progressive disease.
Table 1 shows the relation between response 
to therapy (objective remission and stable dis­
ease) and pre-treatment characteristics. There 
was no statistically significant difference in re­
sponse rates between patients with ER-positive 
and ER-negative primary tumours (7 of 21 and 6 
of 21 respectively, p  > 0.1) and between patients 
receiving one or more prior endocrine treatment 
modalities and patients without prior endocrine 
therapy (15 of 28 and 7 of 19 respectively, p  > 0.1). 
Also no statistical significant difference in re­
sponse rates between pre- and postmenopausal 
women was found (5 of 9 and 16 of 33 respec­
tively, p  > 0,1).
Finally, 7 of 23 and 7 of 24 patients who 
received low-dose and classical adjuvant CMF 
respectively achieved an objective remission. The 
objective remission plus stable disease percent­
ages in both groups were 57 and 38, respectively 
(Table 1, p  > 0.1).
4. Discussion
In this study the objective remission rate to 
palliative CMF chemotherapy in 47 women with 
advanced breast cancer who relapsed after adju­
vant CMF was 30%.
Valagussa et al, [1] described the results of 
CMF retreatment in 29 patients; 41% of these 
achieved an objective remission, which in their 
series was not statistically significantly different 
from the results of CMF in 45 chemotherapy- 
naive patients (objective remission rate = 38%). 
In two other reports results of non-CMF pallia­
tive chemotherapy for patients pretreated with 
the same modalities resulted in objective remis­
sion rates of 25 and 40% [3,4].
The mean percentage of objective remissions 
for all patients treated with comparable regimens 
to their adjuvant therapy is 32% (n = 140, Table
2A). This is of the same order as the objective 
remission rates in patients treated with other 
regimens than those given in the adjuvant setting 
(mean objective remission rate = 28%, range 27- 
39%) [3-7] (Table 2B).
Remission rates for CMF in chemotherapy 
naive patients are reported as 45-53% in litera­
ture data between 1976 and 1991, covering our
w
observation time [9-12].
The median duration of objective remissions in 
our study was 9.5 (range 5-21) months and com­
pares well with that given for palliative CMF 
chemotherapy in general [9-12],
There were no statistically significant differ­
ences in remission rates in different catagories of 
patients according to the predominant localisa­
tion of disease, ER-status and menopausal status. 
However, the subgroups of patients were small.
One of 4 patients who relapsed within 12 
months after the completion of adjuvant 
chemotherapy achieved an objective remission 
during palliative CMF treatment. In accordance, 
Buckner et al. [3] found no difference in response 
rates of patients who started palliative 
chemotherapy within 12 months or > 12 months 
after the completion of adjuvant treatment. In 
contrast, in Valagussa’s study [1] no remission 
was seen in 6 patients who relapsed within 12 
months after adjuvant chemotherapy.
It is of interest that “dose intensity” of adju­
vant CMF did not influence the outcome of pal­
liati ve chemotherapy. However, it should be rec­
ognized that the total amount of chemotherapy 
given was on average higher in the low-dose 
adjuvant CMF group than in the classical adju­
vant CMF group.
As might be expected, survival times for pa­
tients who responded were better than for those 
who failed and this study reinforces the bad prog­
nosis for the latter group (median survival of 6 
months).
In conclusion, previous adjuvant CMF therapy 
does not exclude an objective response during 
palliative therapy with the same regimen in pa­
tients with advanced breast cancer. Although the 
objective remission rate in our study is inferior to 
that for chemotherapy-naive patients, palliative 
CMF therapy with its moderate and well-known
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toxicity should not be rejected for patients who 
have relapsed after adjuvant CMF treatment.
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